Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 248

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 248
---
 (169 | ) |     |      |   (755 | ) |
| Cash and cash equivalents at the beginning of the period                    |     |                  |    345 |   |     |      |  1,240 |   |
| Cash and cash equivalents at the end of the period                          |     | $                |    176 |   |     | $    |    485 |   |
| Non-cash activities:                                                        |     |                  |        |   |     |      |        |   |
| 2021 Notes conversion into preferred D-2 shares                             |     | $                |      - |   |     | $    |  1,086 |   |

<div align='center'>The accompanying notes are an integral part of
the unaudited condensed unaudited financial statements.

F-5</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 1: | GENERAL |

| a. | Regentis Biomaterials Ltd.                                                                                                       
 (the “Company”) commenced operations in September 2004. The Company develops innovative tissue repair solutions that             
 seek to restore the health and enhance the quality of life of patients. The Company’s current efforts are focused on orthopedic  
 treatments using our Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue. Gelrin is a 
 unique hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen. The Company’s lead product                    
 candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee                              
 for the treatment of painful injuries to articular knee cartilage.                                                               |

| b. | Transaction with OceanTech Corp. |

On May 2, 2023, OceanTech Acquisitions
I Corp., a Delaware corporation (“OceanTech”), R.B. Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of
OceanTech (“Merger Sub”), Aspire Acquisition LLC, OceanTech’s sponsor (the “Sponsor”), and the Company
executed a definitive Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which, among other things, Merger
Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger